Drug intelligence / Profile preview

ACR-6840

Development stage: Preclinical
Lead developer: Acrivon Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ACR-6840 is a potential first-in-class, orally bioavailable small molecule inhibitor of Cyclin-dependent kinase 11 (CDK11) developed by Acrivon Therapeutics. Discovered and designed using the proprietary Acrivon Predictive Precision Proteomics (AP3) platform, ACR-6840 is intended to treat solid tumors specifically identified by AP3-derived biomarkers. CDK11 is a key regulator of multiple cellular processes, including transcription, pre-mRNA splicing, and mitosis, and its inhibition represents a novel approach to disrupting the cell cycle in cancer cells. The compound is currently in preclinical development, with an Investigational New Drug (IND) submission anticipated in the fourth quarter of 2026.

Targets

CDK11

Beyond the preview

Go deeper on ACR-6840.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACR-6840.

Explore the full profile